Overexpression of CD133 promotes drug resistance in C6 glioma cells

Molecular Cancer Research

Volumn 8, Issue 8, 2010, Pages 1105-1115

  Angelastro, James M ^a   Lamé, Michael W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; CAMPTOTHECIN; CD133 ANTIGEN; DOXORUBICIN; GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER STEM CELL; CELL ACTIVITY; CELL FUNCTION; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; GLIOMA CELL; MALE; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; UPREGULATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CAMPTOTHECIN; CELL PROLIFERATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GLIOMA; GLYCOPROTEINS; MALE; NEOPLASTIC STEM CELLS; P-GLYCOPROTEIN; PEPTIDES; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

RATTUS;

EID: 77955761867     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0383     Document Type: Article

References (58)

1. Zhang QB, Ji XY, Huang Q, Dong J, Zhu YD, Lan Q. Differentiation profile of brain tumor stem cells: a comparative study with neural stem cells. Cell Res 2006;16:909-15. (Pubitemid 44973578)
2. Zeppernick F, Ahmadi R, Campos B, et al. Stem cellmarker CD133 affects clinical outcomein glioma patients. Clin Cancer Res 2008;14:123-9. (Pubitemid 351377986)
3. Yi JM, Tsai HC, Glockner SC, et al. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res 2008;68:8094-103.
4. Wang J, Sakariassen PO, Tsinkalovsky O, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 2008;122:761-8.
5. Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat Rev Cancer 2006;6:425-36.
6. + cancer stem cells in human solid tumours. PLoS ONE 2008;3:e3469.
7. Thon N, Damianoff K, Hegermann J, et al. Presence of pluripotent CD133(+) cells correlates with malignancy of gliomas. Mol Cell Neurosci 2008;43:51-9.
8. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-8. (Pubitemid 37187480)
9. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401. (Pubitemid 39551674)
10. Singh S, Dirks PB. Brain tumor stem cells: identification and concepts. Neurosurg Clin N Am 2007;18:31-8, viii.
11. Schrot RJ, Ma JH, Greco CM, Arias AD, Angelastro JM. Organotypic distribution of stem cell markers in formalin-fixed brain harboring glioblastoma multiforme. J Neurooncol 2007;85:149-57.
12. Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med 2005;353:811-22.
13. Salnikov AV, Kusumawidjaja G, Rausch V, et al. Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter. Cancer Lett 2008; 275:185-93.
14. Perez Castillo A, Aguilar-Morante D, Morales-Garcia JA, Dorado J. Cancer stem cells and brain tumors. Clin Transl Oncol 2008;10:262-7.
15. Liu W, Shen G, Shi Z, et al. Brain tumour stemcells and neural stemcells: still explored by the same approach? J Int Med Res 2008;36:890-5.
16. Kondo T. Stem cell-like cancer cells in cancer cell lines. Cancer Biomark 2007;3:245-50. (Pubitemid 351492648)
17. Kang MK, Hur BI, Ko MH, Kim CH, Cha SH, Kang SK. Potential identity of multi-potential cancer stem-like subpopulation after radiation of cultured brain glioma. BMC Neurosci 2008;9:15.
18. Joo KM, Kim SY, Jin X, et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest 2008;88:808-15.
19. Hassan HT, Zhai X, Goodacre JA. CD133 stem cells in adult human brain. J Neurooncol 2008;89:247-8; author reply 249.
20. Gunther HS, Schmidt NO, Phillips HS, et al. Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 2008;27:2897-909.
21. Dell'Albani P. Stem cell markers in gliomas. Neurochem Res 2008; 33:2407-15.
22. Beier D, Wischhusen J, Dietmaier W, et al. CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors. Brain Pathol 2008;18:370-7. (Pubitemid 351782845)
23. Altaner C. Glioblastoma and stem cells. Neoplasma 2008;55:369-74.
24. Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 2002; 39:193-206.
25. Zheng X, Shen G, Yang X, Liu W. Most C6 cells are cancer stem cells: evidence from clonal and population analyses. Cancer Res 2007;67:3691-7. (Pubitemid 46762154)
26. Shervington A, Lu C. Expression of multidrug resistance genes in normal and cancer stem cells. Cancer Invest 2008;26:535-42. (Pubitemid 351892589)
27. Shen G, Shen F, Shi Z, et al. Identification of cancer stem-like cells in the C6 glioma cell line and the limitation of current identification methods. In Vitro Cell Dev Biol Anim 2008;44:280-9.
28. Hambardzumyan D, Squatrito M, Holland EC. Radiation resistance and stem-like cells in brain tumors. Cancer Cell 2006;10:454-6. (Pubitemid 44854752)
29. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radio-resistance by preferential activation of the DNA damage response. Nature 2006;444:756-60. (Pubitemid 44949604)
30. Borst P, Jonkers J, Rottenberg S. What makes tumors multidrug resistant? Cell Cycle 2007;6:2782-7.
31. Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells in nervous system tumors. Oncogene 2004;23:7267-73. (Pubitemid 39382160)
32. Mizrak D, Brittan M, Alison MR. CD133: molecule of the moment. J Pathol 2008;214:3-9.
33. Fargeas CA, Huttner WB, Corbeil D. Nomenclature of prominin-1 (CD133) splice variants - an update. Tissue Antigens 2007;69:602-6. (Pubitemid 46733679)
34. Smith LM, Nesterova A, Ryan MC, et al. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 2008;99:100-9. (Pubitemid 351920235)
35. Woodward WA, Sulman EP. Cancer stem cells: markers or biomarkers? Cancer Metastasis Rev 2008;27:459-70.
36. + cells with cancer stem cell characteristics. Breast Cancer Res 2008;10:R10.
37. LaBarge MA, Bissell MJ. Is CD133 a marker of metastatic colon cancer stem cells? J Clin Invest 2008;118:2021-4.
38. Jaszai J, Fargeas CA, Florek M, Huttner WB, Corbeil D. Focus on molecules: prominin-1 (CD133). Exp Eye Res 2007;85:585-6.
39. Corbeil D, Roper K, Weigmann A, Huttner WB. AC133 hematopoietic stem cell antigen: human homologue of mouse kidney prominin or distinct member of a novel protein family? Blood 1998;91:2625-6.
40. Corbeil D, Roper K, Fargeas CA, Joester A, Huttner WB. Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2001;2:82-91. (Pubitemid 32219860)
41. Roper K, Corbeil D, Huttner WB. Retention of prominin in microvilli reveals distinct cholesterol-based lipid micro-domains in the apical plasma membrane. Nat Cell Biol 2000;2:582-92.
42. Shmelkov SV, St Clair R, Lyden D, Rafii S. AC133/CD133/Prominin-1. Int J Biochem Cell Biol 2005;37:715-9.
43. Maw MA, Corbeil D, Koch J, et al. A frameshift mutation in prominin (mouse)-like 1 causes human retinal degeneration. Hum Mol Genet 2000;9:27-34. (Pubitemid 30145285)
44. Zacchigna S, Oh H, Wilsch-Brauninger M, et al. Loss of the cholesterol-binding protein prominin-1/CD133 causes disk dysmorphogenesis and photoreceptor degeneration. J Neurosci 2009;29:2297-308.
45. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84. (Pubitemid 40488633)
46. Weigmann A, Corbeil D, Hellwig A, Huttner WB. Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl Acad Sci U S A 1997;94:12425-30. (Pubitemid 27492544)
47. Angelastro JM, Canoll PD, Kuo J, et al. Selective destruction of glioblastoma cells by interference with the activity or expression of ATF5. Oncogene 2006;25:907-16. (Pubitemid 43237709)
48. Immervoll H, Hoem D, Sakariassen PO, Steffensen OJ, Molven A. Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer 2008;8:48.
49. Saigusa S, Tanaka K, Toiyama Y, et al. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol 2009;16:3488-98.
50. Giebel B, Corbeil D, Beckmann J, et al. Segregation of lipid raft markers including CD133 in polarized human hematopoietic stem and progenitor cells. Blood 2004;104:2332-8. (Pubitemid 39331830)
51. Pfenninger CV, Roschupkina T, Hertwig F, et al. CD133 is not present on neurogenic astrocytes in the adult subventricular zone, but on embryonic neural stem cells, ependymal cells, and glioblastoma cells. Cancer Res 2007;67:5727-36. (Pubitemid 46985005)
52. Karbanova J, Missol-Kolka E, Fonseca AV, et al. The stem cell marker CD133 (prominin-1) is expressed in various human glandular epithelia. J Histochem Cytochem 2008;56:977-93.
53. + neural stem cells in the ependyma of mammalian postnatal forebrain. Proc Natl Acad Sci U S A 2008;105:1026-31.
54. Sayan BS, Sayan AE, Knight RA, Melino G, Cohen GM. p53 is cleaved by caspases generating fragments localizing to mitochondria. J Biol Chem 2006;281:13566-73. (Pubitemid 43855270)
55. Benda P, Lightbody J, Sato G, Levine L, Sweet W. Differentiated rat glial cell strain in tissue culture. Science 1968;161:370-1.
56. Scoazec JY, Bringuier AF, Medina JF, et al. The plasma membrane polarity of human biliary epithelial cells: in situ immunohistochemical analysis and functional implications. J Hepatol 1997;26:543-53.
57. Radel S, Fredericks W, Mayhew E, Baker R. P-glycoprotein expression and modulation of cell-membrane morphology in Adriamycin-resistant P388 leukemia cells. Cancer Chemother Pharmacol 1990;25:241-6. (Pubitemid 20014965)
58. Collins VP. Brain tumours: classification and genes. J Neurol Neurosurg Psychiatry 2004;75 Suppl 2:ii2-11.